G.R. Thompson, The scientific basis and future of lipoprotein apheresis. Ther. Apher Dial. 26, 32–36 (2022)
F. Kronenberg, S. Mora, E.S.G. Stroes, B.A. Ference, B.J. Arsenault, L. Berglund, M.R. Dweck, M. Koschinsky, G. Lambert, F. Mach, C.J. McNeal, P.M. Moriarty, P. Natarajan, B.G. Nordestgaard, K.G. Parhofer, S.S. Virani, von A. Eckardstein, G.F. Watts, J.K. Stock, K.K. Ray, L.S. Tokgözoğlu, A.L. Catapano, Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a Euro-pean atherosclerosis society consensus statement. Eur. Heart J. 43, 3925–3946 (2022)
Article PubMed PubMed Central CAS Google Scholar
G. Chiesa, M.G. Zenti, A. Baragetti, C.M. Barbagallo, C. Borghi, F. Colivicchi, A.P. Maggioni, D. Noto, M. Pirro, A.A. Rivellese, T. Sampietro, F. Sbrana, M. Arca, M. Averna, A.L. Catapano, Consensus document on Lipoprotein(a) from the Italian society for the study of atherosclerosis (SISA). Nutr. Metab. Cardiovasc. Dis. 33, 1866–1877 (2023)
Article PubMed CAS Google Scholar
L. Connelly-Smith, C.R. Alquist, N.A. Aqui, J.C. Hofmann, R. Klingel, O.A. Onwuemene, C.J. Patriquin, H.P. Pham, A.P. Sanchez, J. Schneiderman, V. Witt, N.D. Zantek, N.M. Dunbar, Guidelines on the use of therapeutic apheresis in clinical Practice - Evidence-Based approach from the writing committee of the American society for apheresis: the ninth special issue. J. Clin. Apher. 38, 77–278 (2023)
U. Julius, S. Fischer, U. Schatz, J. Passauer, S. Bornstein, Why an apheresis center should offer more than one lipoprotein apheresis method. Ther. Apher Dial. 17, 179–184 (2013)
Article PubMed CAS Google Scholar
H. Baumgartner, H.J. Chair, J. Co-Chair, Bermejo, J.B. Chambers, T. Edvardsen, S. Goldstein, P. Lancellotti, M. LeFevre, F. Jr Miller, C.M. Otto, Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European association of cardiovascular imaging and the American society of echocardiography. Eur. Heart J. Cardiovasc. Imaging. 18, 254–275 (2017)
N. Lelli, R. Garuti, M. Ghisellini, R. Tiozzo, M. Rolleri, V. Aimale, E. Ginocchio, A. Naselli, S. Bertolini, S. Calandra, Occurrence of multiple aberrantly spliced mRNAs of the LDL-receptor gene upon a donor splice site mutation that causes Familial high-cholesterolemia (FHBenevento). J. Lipid Res. 36, 1315–1324 (1995)
Article PubMed CAS Google Scholar
T. Sampietro, F. Sbrana, F. Bigazzi, A. Ripoli, B. Dal Pino, Null receptor homozygous Familial highcholesterolaemia: quoad valetudinem long life treatment. Eur. J. Prev. Cardiol. 27, 2105–2108 (2020)
V.J.J. Schettler, E. Schettler, Beyond cholesterol-pleiotropic effects of lipoprotein apheresis. Ther. Apher Dial. 26, 35–40 (2022)
Article PubMed CAS Google Scholar
T. Sampietro, F. Sbrana, F. Bigazzi, A. Ripoli, B. Dal Pino, E.M. Pasanisi, C. Petersen, M. Coceani, R. Luciani, M. Pianelli, The inci-dence of cardiovascular events is largely reduced in patients with maximally tolerated drug therapy and lipoprotein apheresis. A single-center experience. Atheroscler Suppl. 18, 268–272 (2015)
Article PubMed CAS Google Scholar
E. Braunwald, Aortic Stenosis, A 6-Decade odyssey. J. Am. Coll. Cardiol. 82, 2110–2112 (2023)
F. Bigazzi, F. Sbrana, D. Berretti, M.G. Zenti, S. Zambon, A. Fabris, M. Fonda, G.B. Vigna, G. D’Alessandri, S. Passalacqua, B. Dal Pino, M. Pianelli, R. Luciani, A. Ripoli, D. Rafanelli, E. Manzato, L. Cattin, T. Sampietro, Reduced incidence of cardiovascular events in high-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo interdisciplinare aferesi Lipoproteica) pilot study. Transfus. Apher Sci. 57, 661–664 (2018)
V.J.J. Schettler, N. Selke, S. Jenke, T. Zimmermann, G. Schlieper, W. Bernhardt, F. Heigl, P. Grützmacher, I. Löhlein, R. Klingel, B. Hohenstein, W. Ramlow, A. Vogt, U. Julius, Scientific Board of GLAR for the German Apheresis Working Group. The Ger-man Lipoprotein Apheresis Registry-Summary of the eleventh annual report. Atherosclerosis. 2024; 398: 118601
J.Y. Ong, S.M.L. Tan, A.S. Koh, W. Kong, C.H. Sia, T.C. Yeo, S.C. Quek, K.K. Poh, Novel Circulating biomarkers in aortic valve Ste-nosis. Int. J. Mol. Sci. 26, 1902 (2025)
Article PubMed PubMed Central CAS Google Scholar
M.L. Koschinsky, A. Bajaj, M.B. Boffa, D.L. Dixon, K.C. Ferdinand, S.S. Gidding, E.A. Gill, T.A. Jacobson, E.D. Michos, M.S. Safarova, D.E. Soffer, P.R. Taub, M.J. Wilkinson, D.P. Wilson, C.M. Ballantyne, A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J. Clin. Lipidol. 18, e308–e319 (2024)
F. Sbrana, F. Bigazzi, C. Corciulo, B. Dal Pino, Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy. Eur. J. Prev. Cardiol. 31, e62–e64 (2024)
Q. Ciampi, A. Zagatina, L. Cortigiani, K. Wierzbowska-Drabik, J.D. Kasprzak, M. Haberka, A. Djordjevic-Dikic, B. Beleslin, A. Boshchenko, T. Ryabova, N. Gaibazzi, F. Rigo, C. Dodi, I. Simova, M. Samardjieva, A. Barbieri, D. Morrone, V. Lorenzoni, C. Prota, B. Villari, F. Antonini-Canterin, M. Pepi, C. Carpeggiani, P.A. Pellikka, E. Picano, Prognostic value of stress echocar-diography assessed by the ABCDE protocol. Eur. Heart J. 42, 3869–3878 (2021)
Comments (0)